Ninety-two percent of pancreatic cancers with KRAS mutations can promote the recruitment of MDSCs and Tregs through the secretion of cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) [148,149,150]. The gene discussed is KRAS; the disease is pancreatic neoplasm.